TY -的A2 - La Torre,朱塞佩盟——Suwantika Auliya a . AU - Zakiyah内伊盟——Abdulah Rizky盟——Sitohang Vensya AU - Tandy热特鲁迪斯牛非盟- Anartati Atiek盟——Hidayatullah Tetrawindu盟——Herliana Putri盟——Hadinegoro Sri r . PY - 2021 DA - 2021/04/27 TI -肺炎球菌疫苗的成本效益和预算影响分析印尼SP - 7494965六世- 2021 AB -作为一个国家的大量死亡由于肺炎球菌病,印尼还没有包括肺炎球菌疫苗接种到例行程序。本研究旨在分析肺炎球菌疫苗的成本效益和预算影响在印尼通过开发一个非自治队列模型。在比较没有接种疫苗,使用两种疫苗(PCV10和PCV13)在两个定价场景(联合国儿童基金会和政府合同价格)考虑。估计成本效益值,5年的时间范围是由个人的推断结果应用在模拟队列,直到5岁个月分析周期。估计负担能力值,6期(2019 - 2024)采用考虑政府对肺炎球菌疫苗接种的战略计划。在没有接种疫苗的比较,结果表明,疫苗接种肺炎球菌病减少1702548和2268411例在使用PCV10 PCV13,分别。疫苗接种有可能降低最高的治疗成本从付款人的角度在5360万美元和7140万美元PCV10 PCV13,分别。联合国儿童基金会申请价格,增量成本效益比率(冷藏工人)从医疗的角度将218美元和162美元每QALY-gained PCV10 PCV13,分别。申请政府合同价格,冷藏工人将987美元和747美元每QALY-gained PCV10 PCV13,分别。结果证实,PCV13比PCV10与价格更划算。 In particular, introduction cost per child was estimated to be $0.91 and vaccination cost of PCV13 per child (3 doses) was estimated to be $16.61 and $59.54 with UNICEF and government contract prices, respectively. Implementation of nationwide vaccination would require approximately $73.3–$75.0 million (13–14% of routine immunization budget) and $257.4-$263.5 million (45–50% of routine immunization budget) with UNICEF and government contract prices, respectively. Sensitivity analysis showed that vaccine efficacy, mortality rate, and vaccine price were the most influential parameters affecting the ICER. In conclusion, pneumococcal vaccination would be a highly cost-effective intervention to be implemented in Indonesia. Yet, applying PCV13 with UNICEF price would give the best cost-effectiveness and affordability values on the routine immunization budget. SN - 1687-9805 UR - https://doi.org/10.1155/2021/7494965 DO - 10.1155/2021/7494965 JF - Journal of Environmental and Public Health PB - Hindawi KW - ER -